Pharmaceutical market grows 8.7% in August; cardiac and anti-diabetic segments lead

India’s pharmaceutical market registered strong performance in August 2025, with total market value rising 8.7% YoY to Rs. 20,984 crore (US$ 2.38 billion), according to Pharmarack data. Growth was led by cardiac, anti-diabetic, and anti-neoplastic therapies, with the latter posting a sharp 19.7% rise. The cardiac and anti-diabetic segments expanded 13.2% and 9.4%, respectively, underscoring strong demand for chronic and specialty treatments. Market volumes also increased modestly by 1.2%.

Sun Pharma maintained its leadership with an 8.3% share and 13.7% growth, followed by Abbott and Mankind, each holding 5.9% of the market. Other key contributors included Cipla, Alkem, Intas, and Torrent, supported by strong brand performance from Augmentin, Glycomet GP, Pan, and Liv.52, which grew 13.9%. Rising demand in respiratory and anti-neoplastic therapies further boosted overall growth. With chronic therapies, seasonal vaccination campaigns, and specialty medicine launches, the Indian Pharmaceutical Market is poised for sustained expansion in the coming months.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.